Peptides, active-site peptidomimetic and metabotropic inhibitors, ASOs, aptamers, and monoclonal antibodies are all methods for blocking the FXI/FXIa system to provide a range of treatment alternatives to address the requirements of thrombosis patients. The gene discussed is F11; the disease is deep vein thrombosis.